You are using an outdated browser. Please upgrade your browser to improve your experience and security.

PROFESSIONAL EXPERIENCES WITH REMODULIN

These videos feature expert healthcare professionals who have treated with Remodulin and are dedicated to helping patients live with PAH. Learn more about their experiences treating with Remodulin.

UT does not provide medical advice.

Triggers for Escalation

When is it appropriate to escalate treatment to parenteral prostacyclin therapy? Paul Forfia, MD, discusses his approach and the importance of serial assessment of the right heart function.

Adjusting to COVID-19

Ronald Oudiz, MD, talks through how he effectively manages his parenteral prostacyclin patients with PAH, despite the challenges posed by COVID-19.

Dosing

Robert Schilz, DO, explains the importance of optimized dosing with Remodulin while balancing the art and science of titrating to therapeutic effect.

Elements of a Successful Start on SC Remodulin

John Kingrey, MD, describes how he empowers his patients for a successful initiation with SC therapy and partners with them to proactively manage site pain.

Routes of Administration

When treating with Remodulin, it’s important to know the benefits and risks of SC and IV administration. Stacy A. Mandras, MD, discusses the factors considered for both.

IV=intravenous; PAH=pulmonary arterial hypertension; SC=subcutaneous.

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).